secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enveric Biosciences, Inc. (ENVB)
CIK:        0000890821
Form:       8-K
Filed at:   2026-08-14T20:15:54+00:00
Accession:  0001493152-26-038385
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enveric Biosciences Q2 2026 net loss $3.0M, cash $8.3M, EB-003 IND studies advance
--------------------------------------------------------------------------------

- Net loss $3.0M ($0.76/share) vs $2.5M ($11.65/share) in Q2 2025; cash $8.3M at June 30, 2026.
- Raised $5.0M gross from private placement plus $1.5M from warrant exercises during Q2.
- Advanced EB-003 IND-enabling studies: genotoxicity initiated, non-hallucinogenic GloSensor data, no photoreactivity.
- Secured U.S. Patent 12,605,361 for EVM301 series; received USPTO Notice of Allowance for EVM401 series.
- Plans IND submission and Phase 1 trial for EB-003 in H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/890821/000149315226038385/0001493152-26-038385-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/890821/000149315226038385/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-038385

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer